Literature DB >> 17078209

siRNA: a potential tool for future breast cancer therapy?

Gro Leite Størvold1, Tone Ikdahl Andersen, Charles M Perou, Eirik Frengen.   

Abstract

The siRNA technology is a promising research tool for use in functional genomics, and it also shows potential for use in future therapy. Thus far, siRNAs have been used to specifically silence disease-associated alleles in animal models. The technology is still quite new, and the biological mechanisms underlying RNAi and siRNA-mediated knockdown of gene expression are not yet fully understood. The main issues when siRNAs are designed are efficiency and specificity, and it is of great importance to consider possible off-target effects in the siRNA design. One major challenge in siRNA-based therapy is the development of systems for efficient delivery to the target cells. A large number of tools have, over the last few years, been designed for the delivery of DNA and RNA for gene therapy, and extensive efforts are now placed into developing clinical applications of siRNAs in a range of human diseases, including breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078209     DOI: 10.1615/critrevoncog.v12.i1-2.70

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  7 in total

1.  Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein.

Authors:  Y Shao; Y Liu; C Shao; J Hu; X Li; F Li; L Zhang; D Zhao; L Sun; X Zhao; D J Kopecko; D V Kalvakolanu; Y Li; D Q Xu
Journal:  Cancer Gene Ther       Date:  2010-08-13       Impact factor: 5.987

2.  siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells.

Authors:  Xiao-Yu Li; Qi-Feng Luo; Chuan-Kui Wei; Deng-Feng Li; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

3.  Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Authors:  Cornelia Braicu; Valentina Pileczki; Laura Pop; Roxana Cojocneanu Petric; Sergiu Chira; Eve Pointiere; Patriciu Achimas-Cadariu; Ioana Berindan-Neagoe
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

Review 4.  Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.

Authors:  Behrad Darvishi; Leila Farahmand; Keivan Majidzadeh-A
Journal:  Mol Ther Nucleic Acids       Date:  2017-03-29

5.  Antitumor and antimetastatic activities of a novel benzothiazole-2-thiol derivative in a murine model of breast cancer.

Authors:  XiaoLin Hu; Sen Li; Yan He; Ping Ai; Shaoyong Wu; Yonglin Su; Xiaolin Li; Lei Cai; Xingchen Peng
Journal:  Oncotarget       Date:  2017-02-14

6.  Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects.

Authors:  Ioana Berindan-Neagoe; Cornelia Braicu; Alexandru Irimie
Journal:  Int J Nanomedicine       Date:  2012-12-12

7.  p53 siRNA - a therapeutic tool with significant implication in the modulation of apoptosis and angiogenic pathways.

Authors:  Ovidiu Braicu; Valentina Pileczki; Cornelia Braicu; Patriciu Achimas-Cadariu; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Clujul Med       Date:  2015-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.